Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 5-6/2013

01.03.2013 | letter to the editor

Duloxetine-induced life-threatening long QT syndrome

verfasst von: PharmD Matej Štuhec

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 5-6/2013

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Duloxetine hydrochloride (DH) is a potent inhibitor of norepinephrine and serotonin reuptake, with low impact on dopamine uptake. In patients unresponsive to selective serotonin reuptake inhibitors, the administration of DH and bupropion (BUP) is an effective switching strategy [ 1]. …
Literatur
1.
Zurück zum Zitat Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disorders. 2012;136:172–6. PubMedCrossRef Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disorders. 2012;136:172–6. PubMedCrossRef
2.
Zurück zum Zitat Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126–43. PubMedCrossRef Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126–43. PubMedCrossRef
3.
Zurück zum Zitat Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharm. 2007;49:146–53. CrossRef Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharm. 2007;49:146–53. CrossRef
4.
Zurück zum Zitat Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47. PubMedCrossRef Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47. PubMedCrossRef
5.
Zurück zum Zitat Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003;37:999–1002. PubMedCrossRef Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003;37:999–1002. PubMedCrossRef
Metadaten
Titel
Duloxetine-induced life-threatening long QT syndrome
verfasst von
PharmD Matej Štuhec
Publikationsdatum
01.03.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 5-6/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0330-6